A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
Latest Information Update: 13 May 2024
At a glance
- Drugs PF 6412562 (Primary)
- Indications Schizophrenia and disorders with psychotic features
- Focus Therapeutic Use
- 07 May 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2022 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 08 Aug 2022 Planned primary completion date changed from 31 Dec 2023 to 30 Sep 2024.